Nitrous Oxide Analgesia Vaso-occlusive Crisis



Status:Recruiting
Conditions:Anemia
Therapuetic Areas:Hematology
Healthy:No
Age Range:8 - 18
Updated:1/18/2019
Start Date:June 2013
End Date:December 2019
Contact:Daniel S Tsze, MD, MPH
Email:dst2141@columbia.edu
Phone:212-305-9825

Use our guide to learn which trials are right for you!

Nitrous Oxide for Analgesia in Sickle Cell Vaso-occlusive Crisis

Patients who have sickle cell VOC are usually treated with opioids, such as morphine.
However, this current way of treating them has not improved the health, medical outcomes, or
rates of hospitalizations. In addition, since VOC can happen very frequently over a long
period of time, giving opioids over and over again can cause both short-term and long-term
problems. Nitrous oxide (N2O) is a way of treating pain that may provide a better alternative
to repeatedly giving opioids over long periods of time. N2O has been shown to provide up to 3
hours of pain relief in inpatient patients with VOC whose pain did not improve with morphine
infusions, and is used extensively in France, where almost half of 85 pediatric emergency
departments use nitrous oxide to treat children with VOC whose pain did not get better with
standard treatment with morphine. However, pain relief which N2O provides in the acute
setting has not been well described. Therefore, the purpose of our study is to describe how
well N2O can relieve the pain in patients with SCD who present to the emergency department
and are experiencing a VOC.


Inclusion Criteria:

- Patients with sickle cell disease

- Ages 8 to 18, inclusive

- Present to the pediatric emergency department with VOC and whose pain scores remain
greater than or equal to 7/10 on the NRS after initial standard treatment (i.e. IV
fluids, morphine and NSAIDs).

Exclusion Criteria:

- life-threatening illness as determined by attending clinician

- developmental delay

- altered level of consciousness

- any contraindications to receiving N2O

- foster children and wards of the state
We found this trial at
1
site
New York, New York 10032
Principal Investigator: Daniel S Tsze, MD, MPH
?
mi
from
New York, NY
Click here to add this to my saved trials